PP2A A Subunit antibody | knockout validation | Cell Signaling 2041

This is a knockout-validated antibody summary, based on the publication "B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: PP2A A Subunit

Catalog number: 2041

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to the sequence of human PP2A A Subunit protein. Reacts with human, mouse, rat, and monkey. Suitable for western blot, immunohistochemistry (paraffin) and immunofluorescence/immunocytochemistry.

Validation Method

Western blot

Sample

Patient-derived bone marrow-derived B cell lymphoma xenograft cells. Cells were lysed in CelLytic buffer (Sigma-Aldrich) supplemented with 1% protease inhibitor cocktail (Fisher Scientific).

Detection

Western Breeze Immunodetection System (Life Technologies) was used for signal development, and chemiluminescent signal was detected by X-ray film exposure.

Figure

Patient-derived Ph+ ALL xenograft cells were used for doxycycline (Dox)-inducible CRISPR-Cas9-mediated gene disruption of PPP2R1A (3 different gRNAs were used). Western blot was performed to measure expression of PP2A and phosphorylation of H2AX after 3 days of Dox-treatment. Please see Figure 7a in the article [1].

References
  1. Xiao G, Chan L, Klemm L, Braas D, Chen Z, Geng H, et al. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. 2018;173:470-484.e18 pubmed publisher